Mazdutide Research Guide — Oxyntomodulin-Derived GLP-1R/GCGR Dual Agonist, Phase 3 Clinical Data & Metabolic Biology (2026)

Mazdutide (IBI362; LY3305677; YPB.269) is a once-weekly synthetic oxyntomodulin analogue and dual GLP-1R/GCGR agonist developed by Innovent Biologics. In research models, it activates GLP-1R (appetite suppression, gastric emptying delay, glucose-dependent insulin secretion) and GCGR (energy expenditure increase: hepatic fatty acid oxidation, BAT thermogenesis, lipolysis). Both receptor contributions are independently confirmed: weight loss occurs in GCGR KO mice (GLP-1R contribution) AND in GLP1R KO mice (GCGR contribution). Phase 3 GLORY-1 (Chinese obese adults): 11.3–14.84% weight loss at 24–48 weeks; all endpoints met (ADA 2024). Phase 3 DREAMS-1 (T2D): endpoints met. China NMPA NDA (obesity) accepted February 2024. Not research-grade. Research Use Only (RUO). Updated April 2026.

Oxyntomodulin is an endogenous proglucagon-derived peptide produced by intestinal L-cells (alongside GLP-1 and GLP-2) that naturally activates both GLP-1R and GCGR — making it the natural dual GLP-1R/GCGR agonist. Its name derives from its initial characterization as inhibiting oxyntic cell (parietal cell) acid secretion. Oxyntomodulin consists of the 29-amino acid glucagon sequence plus an 8-amino acid C-terminal extension (KKNDWKHNITQ in the full 37-AA form), and its C-terminal extension region contributes to GLP-1R binding affinity. As a natural endogenous peptide, native oxyntomodulin has two key limitations for compound development: very short plasma half-life (minutes) and relatively modest receptor potency vs. synthetic analogs. Mazdutide is an engineered version of the oxyntomodulin scaffold: amino acid substitutions optimize GLP-1R and GCGR binding affinity and selectivity balance, while lipidation extends half-life to approximately 7 days (once-weekly SC dosing). The “oxyntomodulin analogue” designation is mechanistically precise: it identifies mazdutide as an engineered derivative of the natural dual GLP-1R/GCGR agonist, distinguishing its structural origin from glucagon-backbone-derived compounds like survodutide, which introduce GLP-1R activity into the glucagon sequence rather than optimizing from the naturally bifunctional oxyntomodulin scaffold.

Mazdutide and survodutide share the same dual receptor mechanism (GLP-1R + GCGR), the same once-weekly SC administration format, and the same broad clinical goals (obesity and metabolic disease). The key differences are: (1) Structural scaffold: mazdutide is an oxyntomodulin analogue (engineered from the endogenous dual GLP-1R/GCGR agonist peptide); survodutide is a glucagon analogue (engineered from the native glucagon backbone to add GLP-1R activity). Different molecular scaffolds may produce different GLP-1R/GCGR potency ratios and receptor binding kinetics. (2) Developer and geography: mazdutide is developed by Innovent Biologics (China; HKEX-listed) with a China-primary clinical program; survodutide is developed by Boehringer Ingelheim (Germany) with a global clinical program. (3) Clinical stage: mazdutide has completed Phase 3 (GLORY-1, DREAMS-1) and filed NMPA NDA; survodutide’s Phase 3 SYNCHRONIZE program is still ongoing (as of April 2026) without NDA filing. For researchers, both compounds are relevant for studying GLP-1R/GCGR dual agonism; using both in the same experimental system allows scaffold-comparison research — asking whether the oxyntomodulin vs. glucagon structural origin produces different receptor activation profiles or downstream metabolic effects.

GLORY-1 is significant for several reasons beyond the headline weight loss numbers (11.3–14.84% over 24–48 weeks). First, it is the first Phase 3 trial of any GLP-1R/GCGR dual agonist to meet all primary and key secondary endpoints — providing the most rigorous clinical validation of the dual receptor hypothesis for obesity pharmacology. Second, the comprehensive cardio-metabolic endpoints (waist circumference, blood lipids, blood pressure, serum uric acid, liver enzymes, liver fat content) all improved, suggesting the GCGR component’s hepatic fatty acid oxidation effects translate to meaningful liver and metabolic improvements at scale. Third, GLORY-1 was conducted in Chinese subjects — providing the largest GLP-1R/GCGR dual agonist efficacy dataset in an East Asian population, where metabolic disease presentation and BMI thresholds differ from Western cohorts. For researchers, GLORY-1 establishes that the GLP-1R/GCGR dual agonism hypothesis is pharmacologically validated at the Phase 3 level, providing mechanistic confidence for laboratory research using mazdutide as a research tool in metabolic disease models.

The “glucagon paradox” in dual agonist design refers to the apparent contradiction: glucagon normally raises blood glucose via GCGR-mediated hepatic glycogenolysis and gluconeogenesis, yet GLP-1R/GCGR dual agonists like mazdutide improved glucose control (rather than causing hyperglycemia) in T2DM research subjectss in DREAMS-1. The resolution is the same pharmacological design principle used in survodutide: the concurrent GLP-1R activation drives glucose-dependent insulin secretion from pancreatic β-cells that counterbalances GCGR-mediated hepatic glucose output. Because GLP-1R-stimulated insulin secretion is glucose-dependent (amplified only when glucose is elevated, not at euglycemia), it provides an automatic glycemic safety valve without causing hypoglycemia. In DREAMS-1, the combined effect was net glycemic improvement rather than worsening, validating the hypothesis that properly balanced GLP-1R + GCGR co-activation can provide both weight reduction (via GCGR energy expenditure) and glycemic control (via GLP-1R insulin secretion). Mazdutide preclinical data specifically showed that even in GLP1R KO mice, weight loss occurred via GCGR alone — and that GCGR-mediated hepatic fatty acid oxidation contributes directly to liver fat reduction independently of glucose metabolism effects.

Yes. YourPeptideBrand.com provides white-label dropship for mazdutide as YPB.269 (Research Use Only). White-label storefronts include pre-built RUO-compliant product pages with dual GLP-1R/GCGR mechanism descriptions, oxyntomodulin analogue context, GLORY-1 Phase 3 clinical context (clearly framed as research context, China-primary NDA filing, not research-grade), and COA library links. Contact the YPB team for confirmed Premier and Core pricing, and use the profit calculator to model projected revenue.

Every mazdutide batch includes a lot-specific COA: HPLC purity (≥98%), MS confirmation at the correct MW for the lipidated oxyntomodulin analogue form (lipidated MW must be confirmed; non-lipidated form would have dramatically shorter half-life and different pharmacokinetics incompatible with once-weekly research protocols), endotoxin (<1 EU/mg), TAMC, and TYMC. Lipidated MW confirmation is the most critical quality parameter: it is entirely responsible for the extended half-life enabling once-weekly research protocols. All lots are traceable through the batch-specific COA library.

Mazdutide and survodutide are parallel programs for the same pharmacological mechanism — the most direct near-duplicates in the catalog — so positioning must emphasize their differences. Mazdutide: “the first GLP-1R/GCGR dual agonist to complete Phase 3 and file NDA globally; oxyntomodulin-derived scaffold; designed for and validated in the world’s largest obese population (China); fastest-developed compound in the class.” Survodutide: “the global program for GLP-1R/GCGR dual agonism; glucagon-derived scaffold; significant MASH Phase 2 NEJM data showing 64.5% fibrosis reduction; Phase 3 SYNCHRONIZE active for Western populations.” For researchers, the value of both compounds is scaffold comparison: mazdutide (oxyntomodulin scaffold) and survodutide (glucagon scaffold) are the only pair of GLP-1R/GCGR dual agonists available in a white-label research catalog, enabling experiments that directly compare how different molecular scaffolds achieve the same dual receptor activation and whether the scaffold origin affects downstream metabolic effects in the same model system.